ArticleDynorphin a-(1–13)-morphine interactions: Quantitative and qualitative eeg properties differ in morphine-naive vs. Morphine-tolerant rats
-
Add time:09/08/2019 Source:sciencedirect.com
The effects of dynorphin A-(1–13) on cumulative IV morphine-induced EEG and EEG power spectra were studied in naive and morphine-tolerant rats. Adult female Sprague-Dawley rats were implanted with cortical EEG electrodes and permanent indwelling ICV and IV cannulae. In naive rats, dynorphin A-(1–13) quantitatively decreased cumulative IV morphine-induced EEG spectral power as well as qualitatively shifting the relative distribution of spectral power to predominantly faster frequencies. In morphine-tolerant rats, the quantitative and qualitative EEG properties were identical to those in dynorphin A-(1–13) pretreated morphine-naive rats. Thus, dynorphin A-(1–13) pretreatment apparently produced instantaneous acute morphine tolerance. Furthermore, in morphine-tolerant rats, dynorphin A-(1–13) pretreatment quantitatively increased morphine-induced EEG power without qualitatively changing the relative distribution of EEG spectral power. This latter effect may be due to a summation of increased endogenous levels of dynorphin A-(1–13) associated with the development of morphine tolerance and the experimentally administered dynorphin A-(1–13). These results indicate that dynorphin-induced quantitative and qualitative EEG changes of morphine may reflect different underlying processes. That is, quantitative changes may reflect the number of receptors that are activated, while qualitative changes may reflect the nature of the receptor-effector coupling.
We also recommend Trading Suppliers and Manufacturers of dynorphin A (1-13), Ala(2)-Trp(4)- (cas 104746-05-6). Pls Click Website Link as below: cas 104746-05-6 suppliers
Prev:Dynorphin A-( 1-13)-Tyr14Leu15-Phe16-Asn17-Gly18-Pro19: a potent and selective κ opioid peptide
Next:Research reportEffect of chronic treatment with morphine, midazolam and both together on dynorphin(1–13) levels in the rat) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research reportEffect of chronic treatment with morphine, midazolam and both together on dynorphin(1–13) levels in the rat09/09/2019
- Dynorphin A-( 1-13)-Tyr14Leu15-Phe16-Asn17-Gly18-Pro19: a potent and selective κ opioid peptide09/07/2019
- ArticleEffects of high intravenous doses of dynorphin A(1–13) on tail flick latency and central nervous system histology in rats09/06/2019
- Dynorphin A (1–13) in the brain suppresses epinephrine-induced ventricular premature complexes and ventricular tachyarrhythmias09/05/2019
- Dynorphin-A-(1–13) antagonizes morphine analgesia in the brain and potentiates morphine analgesia in the spinal cord09/04/2019
- Behavioral effects and in vivo degradation of intraventricularly administered dynorphin-(1-13) and D-Ala2-dynorphin-(1-11) in rats09/03/2019
- Systemic administration of dynorphin A(1–13) markedly inhibits different behavioural responses induced by cocaine in the mouse09/02/2019
- [D-Ala2,(F5)Phe4]-dynorphin1–13-NH2 (DAFPHEDYN): A potent analog of dynorphin 1–1309/01/2019
- Suppression by dynorphin A-(1–13) of the expression of opiate withdrawal and tolerance in mice☆08/31/2019


